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Anti-HBs positive occult hepatitis B virus carrier blood infectious
in two transfusion recipientsq
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Jean-Pierre Allain4
1Blood Transfusion Center of Slovenia, Ljubljana, Slovenia
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3Chiron/Novartis Europe, Suresnes, France
4Department of Haematology, University of Cambridge, Cambridge, UKBackground/Aims:Occult hepatitis B infection (OBI) in blood donations is not considered infectious when anti-HBs is
present.
Methods: Four months after transfusion of eight blood components during coronary arterial bypass surgery, a 59-year-
old patient developed acute hepatitis B. A second 71-year-old patient transfused with a red cell concentrate (RCC) from
one of these donations had early HBV infection 7 months post-transfusion. Samples were tested for HBV serological
markers and HBV DNA was quantiﬁed and sequenced.
Results:One implicated donation contained anti-HBc, anti-HBs (12 IU/L) and 180 IU/ml of HBV DNA. Previous and
subsequent samples contained 3–10 times lower viral load and slightly variable anti-HBs. Two previous donations did not
cause HBV infection. Recipients of the FFP and RCC from the index donation were both HBV infected and carried geno-
type D strains with sequences identical to the donor strain.
Conclusions:Despite anti-HBs, an OBI carrier transmitted HBV to two immunocompetent transfusion recipients.
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body to hepatitis B virus core antigen; anti-HBs, antibody to hepatitis
B virus surface antigen; QPCR, real-time PCR; BCP/PC, basic core
promoter/pre-core.1. Introduction
In Slovenia, approximately 100,000 donations per
year are collected. However, in 2005–2007, six cases of
HBV transmission by transfusion were reported. Inci-
dence was probably underestimated due to a high fre-
quency of subclinical infection. Since HBsAg
serological screening with a sensitive assay is systemati-
cally performed, transfusion transmission of HBV can
originate from either recent infections in the pre-HBsAg
seroconversion window period or occult HBV infection
(OBI). OBI is deﬁned as an atypical carrier state charac-
terized by the presence of HBV DNA in plasma without
detectable hepatitis B surface antigen (HBsAg) with or
without antibodies to hepatitis B core antigen (anti-
HBc) and hepatitis B surface antigen (anti-HBs) [1].Published by Elsevier B.V. All rights reserved.
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carry the risk of transmission, particularly in the pre-
HBsAg window phase [2]. However, the transmission
risk of OBIs is not well deﬁned, although some cases
of OBIs with anti-HBc only infectious by transfusion
were described [2,3].
HBV transmission by blood components from a sin-
gle anti-HBs positive OBI donation to two recipients is
presented.2. Case report
A patient who had been transfused 4 months previ-
ously with ﬁve units of fresh frozen plasma (FFP) and
three units of RCC was suspected of acute hepatitis B.
Stored samples from each implicated donation were
tested for HBV markers. Seven samples were HBV mar-
ker negative. One sample was anti-HBc reactive and
contained HBV DNA. The implicated donor was identi-
ﬁed and stored samples from eight previous donations
and one donation subsequent to the index donation as
well as three follow-up samples were tested for HBV
markers.
The ﬁrst recipient of an FFP unit from the index
donation was a 59-year-old male who was screened neg-
ative for HBV markers 3 days prior to cardiac arterial
bypass. He was transfused on 23rd June, 2005. Four
months later, clinical and laboratory evidence of acute
Hepatitis B was obtained. ALT level was 1821 IU/L,
HBsAg and anti-HBc IgM became reactive. No sample
was available for HBV DNA testing. In a sample col-
lected 4 months later, HBsAg was undetectable, IgM
anti-HBc remained present and HBV DNA was at low
level (Table 1).Table 1
Hepatitis B virus markers in the OBI donor and two HBV infected recipients
Time from Index
donation (m)
HBsAg Anti-HBc Anti-HBc IgM
Donor 45  + ND
37  + ND
31  + ND
23  + ND
19  + ND
13  + ND
6  + ND
Index  + ND
+3  + ND
+7  + ND
+12  ND ND
+16  + ND
Recipient 1 3 days   ND
+4 + + +
+8  + +
Recipient 2 +7 +  
+14  + +
, non-reactive; ND, not done; Neg, negative.The second recipient of the index donation was a 71-
year-old female who received two units of RCC follow-
ing orthopedic surgery. No pre-surgical HBV screening
was performed and no post-surgical evidence of
HBV infection was noted. A blood sample obtained
7 months after transfusion was anti-HBc negative but
HBsAg positive and contained a high level of HBV
DNA (Table 1). Nine months post-transfusion, ALT
level was 566 IU/L. At 14 months post-transfusion the
patient had recovered.
2.1. Methods
Routine blood donation screening for HBsAg was
performed using Abbott PRISM (Abbott laboratories,
Delkenheim, Germany). HBsAg repeat testing, anti-
HBc and anti-HBs assays were performed with Abbott
AxSYM. Cobas Amplicor HBV Monitor (Roche, Basel,
Switzerland) and in-house real-time PCR (QPCR) as
previously described were used to detect and quantify
HBV DNA [4]. Basic core promoter/pre-core region
(BCP/PC), Pre-S/S regions and full HBV genome were
ampliﬁed, sequenced and phylogenetically analyzed as
described [5].3. Results and discussion
The index donation met the criteria deﬁning ‘occult’
hepatitis B virus carriage since the plasma contained
no detectable HBsAg but HBV DNA, anti-HBc and
low titer of anti-HBs. This pattern was consistent 7
and 16 months after the index donation. Seven prior
donations carried anti-HBc and anti-HBs although
HBV DNA ranged between 7 and 63 IU/ml when testedAnti-HBs (IU/L) HBV DNA (IU/ml) HBV genotype
Amplicor QPCR
29 Neg 63
15 Neg Neg
16 Neg 35
16 Neg 45
19 Neg 7
15 Neg ND
15 Neg ND
12 <60 180 D
53 Neg ND
31 Neg 16
ND ND Neg
25 Neg 40
 ND ND
 ND ND
 12 185 D
 1.1  106 1.7  108 D
 Neg ND
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undetectable by a commercial assay except in the Index
sample. This pattern indicates recovery from >5 years
past HBV infection (Table 1). Despite being tested with
the high sensitivity assay, two of the nine donor samples
tested remained HBV DNA negative, suggesting ﬂuctu-
ations of viremia. Prior to the index donation, anti-HBs
levels were essentially stable (15–29 IU/L) but increased
from 12 to 53 IU/L 3 months later suggesting minimal
immune response. There was no clinical evidence that
14 previous donations and one subsequent donation
were infectious to recipients. Pre- and post-transfusion
samples from recipients of 71 and 13 month-dona-
tions showed no serological evidence of HBV infection.
The 71 recipient was negative for HBsAg, anti-HBc
and anti-HBs pre-transfusion, and 4 months post-trans-
fusion, HBsAg was negative but anti-HBc was not
tested. The 13 month recipient did not carry HBsAg,
anti-HBc or anti-HBs 42 months after transfusion.
In contrast, there is strong evidence that both recipi-
ents of the index donation were HBV infected since
acute hepatitis B occurred in recipient 1, 4 months after
transfusion. In recipient 2, the 7-month post-transfusion
sample containing HBsAg and high HBV DNA load
without anti-HBc strongly suggested recent acute HBV
infection and was followed by serological evidence of
recovery (Table 1). A high ALT level 9 months post-
transfusion that normalized after 14 months further
supported this conclusion. The 4-month and probably
7-month long incubation time observed in recipients 1
and 2, respectively, could be explained by a relatively
low infectious dose further decreased by partial anti-
HBs neutralization (calculated on the basis of 180 IU/
ml of HBV DNA and 200 ml of FFP for recipient 1 at
200,000 copies and 20,000 copies in 20 ml of RCC
plasma for recipient 2). Published data indicated that
lower infectious dose prolonged HBV incubation time
and milder symptoms [6]. Transfusion transmission
was further demonstrated by the Pre-S/S sequence iden-
tity between the index donation, recipient 1 and recipi-
ent 2 strains from follow-up samples. The whole
genome sequences of recipient 2 and index donation
were identical. Strains were of genotype D. Of note,
the deduced amino acid sequence of the S protein was
wild-type when compared to the genotype D consensus
sequence except for A117T and S133Y, neither of these
substitutions being recognized as escape mutants. An
escape mutant mechanism explaining the infectivity of
the index donation but not of the other donations from
the donor was thus excluded. Similar cases of break-
through HBV infection with wild-type strains have been
described [7]. Although suppression of the HBV replica-
tion and gene expression is a reported cause of occult
HBV [8], no mutation in the parts of the genome impli-
cated in replication was found. Imperfect containmentof viral replication by the donor immune system is the
most likely cause of low levels of HBV DNA.
The stability of HBV DNA load and anti-HBs in
multiple samples preceding the index donation and
tested simultaneously contained 6–10 times less viral
DNA than the index donation (Table 1). It is therefore
speculated that the main factor singling out the index
donation was a temporarily higher viral load suﬃcient
to overcome the relatively weak neutralizing capacity
of a low anti-HBs level (Table 1). This interpretation
is supported by the subsequent increase in anti-HBs level
suggesting a weak immune response.
Published data reporting the infectivity of OBIs by
transfusion are rare. One case of transmission by a
donation carrying anti-HBc without anti-HBs was
reported in Japan [2]. Another study reported ﬁve
donors (4 genotype D, one genotype A2) with OBI also
carrying only anti-HBc transmitting to recipients. Of 51
traced recipients, 28 (54.9%) either developed fulminant,
fatal, hepatitis B (3 cases) or carried anti-HBc post-
transfusion although no pre-transfusion testing was
performed [3]. In the Japanese study, 16 donations
contained both anti-HBc and anti-HBs and no evidence
of HBV transmission was found [2] conﬁrming previous
results [9]. The two cases reported here appear to be the
ﬁrst related to an OBI donor with anti-HBs. Data col-
lected in Poland indicated that approximately 50% of
OBIs in asymptomatic, apparently healthy, blood
donors carry anti-HBs [10] and that levels of DNA
and anti-HBs are variable as reported here.
Considering that the recipients at age 59 and 71,
respectively, might have presented a mild, age-related,
immunodeﬁciency added to the trauma of major surgery
might have played a role in increasing susceptibility to
viral infection [11]. The fact that approximately 50%
of recipients of blood components in Western Europe
present some degree of immunodeﬁciency related to
age, chemotherapy or therapeutic immunosuppression
suggests an increased susceptibility to HBV infection
[12]. Limited but convincing evidence that OBIs can be
infectious and can be detected by HBV DNA screening
should be carefully considered by the health authorities
of countries where neither anti-HBc nor HBV NAT are
implemented.
Despite their apparent uniqueness, our two cases of
HBV transmission need to be factored in discussions
regarding HBV blood safety policy. They clearly illus-
trate that the neutralizing capacity of low-level anti-
HBs is limited and reinforce the validity of considering
anti-HBs below 100 IU/L to be poorly protective from
infectivity when HBV DNA is present. However, even
in the presence of higher levels of anti-HBs, in a severely
immunodeﬁcient recipient, HBV DNA-containing
blood might be infectious and the clinical expression
severe.
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